Overview

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2022-10-28
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of JAB-3068 administered in investigational regimens in adult participants with advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jacobio Pharmaceuticals Co., Ltd.
Collaborator:
AbbVie
Treatments:
Immune Checkpoint Inhibitors